CHICAGO & DUBLIN--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...
The Food and Drug Administration as approved the first generic of a drug used to treat severe hypoglycemia. The agency has approved a generic glucagon for injection, 1 mg, from Amphastar ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...
SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch and availability of Gvoke VialDx™ (glucagon injection). Gvoke VialDx (glucagon ...
Eighteen hospitalized male diabetic patients, thirty to sixty-nine years of age, were studied. The known duration of the diabetes in the group ranged from one to twenty-five years. All patients ...
Please provide your email address to receive an email when new articles are posted on . The FDA on Wednesday approved the first nasal glucagon powder for the emergency treatment of severe hypoglycemia ...
First concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc. ® is pleased to announce the commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results